Neuberger Berman Group LLC Has $7.87 Million Holdings in Vericel Co. (NASDAQ:VCEL)

Neuberger Berman Group LLC grew its holdings in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 63.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 143,266 shares of the biotechnology company's stock after acquiring an additional 55,555 shares during the period. Neuberger Berman Group LLC owned about 0.29% of Vericel worth $7,867,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Meeder Asset Management Inc. grew its position in shares of Vericel by 8.4% during the fourth quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company's stock worth $129,000 after buying an additional 183 shares in the last quarter. Atria Investments Inc lifted its position in shares of Vericel by 2.4% during the fourth quarter. Atria Investments Inc now owns 7,952 shares of the biotechnology company's stock worth $437,000 after purchasing an additional 184 shares during the last quarter. Louisiana State Employees Retirement System increased its holdings in Vericel by 0.8% in the fourth quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company's stock valued at $1,312,000 after buying an additional 200 shares during the last quarter. Avantax Advisory Services Inc. raised its stake in Vericel by 1.7% during the fourth quarter. Avantax Advisory Services Inc. now owns 13,803 shares of the biotechnology company's stock valued at $758,000 after buying an additional 234 shares in the last quarter. Finally, Linden Thomas Advisory Services LLC grew its position in shares of Vericel by 1.1% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 43,781 shares of the biotechnology company's stock worth $2,404,000 after acquiring an additional 489 shares in the last quarter.

Remove Ads

Vericel Trading Up 1.9 %

VCEL stock traded up $0.79 on Tuesday, hitting $42.02. 437,192 shares of the company's stock traded hands, compared to its average volume of 390,755. Vericel Co. has a 1-year low of $37.76 and a 1-year high of $63.00. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of 700.45 and a beta of 1.61. The stock has a fifty day moving average of $48.80 and a 200-day moving average of $51.46.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Stephens reaffirmed an "overweight" rating and issued a $65.00 price objective on shares of Vericel in a report on Wednesday, January 15th. StockNews.com upgraded Vericel from a "sell" rating to a "hold" rating in a research note on Saturday, March 8th. HC Wainwright reissued a "buy" rating and issued a $60.00 price target on shares of Vericel in a report on Friday, February 28th. Canaccord Genuity Group increased their target price on Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. Finally, Truist Financial lowered their price target on shares of Vericel from $61.00 to $51.00 and set a "buy" rating for the company in a research report on Friday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $60.86.

Insider Buying and Selling

In other Vericel news, Director Robert L. Md Zerbe sold 2,500 shares of the business's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total value of $156,250.00. Following the transaction, the director now owns 26,595 shares in the company, valued at $1,662,187.50. The trade was a 8.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jonathan Siegal sold 1,092 shares of the firm's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $61.99, for a total value of $67,693.08. Following the sale, the insider now directly owns 1,206 shares of the company's stock, valued at $74,759.94. This trade represents a 47.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 58,942 shares of company stock valued at $2,724,548. Corporate insiders own 5.20% of the company's stock.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.